StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY – Free Report) in a report released on Thursday. The brokerage issued a hold rating on the stock.
NovaBay Pharmaceuticals Price Performance
NYSE:NBY opened at $0.54 on Thursday. NovaBay Pharmaceuticals has a one year low of $0.36 and a one year high of $44.80. The company has a fifty day moving average price of $1.71 and a 200 day moving average price of $3.29. The stock has a market cap of $582,116.00, a P/E ratio of 0.00 and a beta of 0.83.
NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($1.37) earnings per share (EPS) for the quarter. NovaBay Pharmaceuticals had a negative return on equity of 304.39% and a negative net margin of 80.76%. The company had revenue of $2.40 million for the quarter. As a group, equities research analysts anticipate that NovaBay Pharmaceuticals will post -5.24 EPS for the current year.
Institutional Trading of NovaBay Pharmaceuticals
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
See Also
- Five stocks we like better than NovaBay Pharmaceuticals
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- This Small Cap Wealth Management Stock Could Provide Big Returns
- 3 Monster Growth Stocks to Buy Now
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Overbought Stocks Explained: Should You Trade Them?
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.